GemPharmatech Co., Ltd. was founded in 2017 and is headquartered in Nanjing, China. The company was established under the scientific leadership of Dr Xiang Gao, PhD, President, a distinguished professor at Nanjing University with over 20 years of experience in generating and analysing animal models, and the recipient of China’s National Distinguished Young Scientists Fund and the Chang Jiang Scholars Programme appointment. Dr Gao also serves as Director of the National Genetic Engineering Mouse Resource Center in China, and his team received the Second Prize of the National Science and Technology Progress Award for the development and application of genetically engineered mouse models.

In the United States, GemPharmatech operates through GemPharmatech USA, with offices in San Diego, California and Cambridge, Massachusetts. The US entity is led by Chief Executive Officer Brandy Wilkinson, PhD, who brings over 15 years of experience in contract vivarium management and preclinical CRO operations, including prior roles at Explora BioLabs (acquired by Charles River Laboratories in 2022), Covance (now LabCorp Drug Development), Champions Oncology, and The Jackson Laboratory.

GemPharmatech’s global infrastructure includes over 30,000 square metres of Specific Pathogen Free (SPF) animal facilities with a cage capacity exceeding 230,000 SPF cages and an annual model generation capacity of over 6,000 new strains. The company’s mouse model catalogue — the world’s largest — encompasses over 25,000 strains, including an extensive Knockout All Project (KOAP) collection of knockout and conditional knockout mice. The company maintains a global distributor network and serves clients across the United States, Europe, and Asia-Pacific. Its website operates in English, Chinese, Japanese, and Korean, reflecting its broad international client base.

Key Products and Services

Mouse Model Catalogue

• Knockout (KO) and Conditional Knockout (cKO) Mouse Models — an extensive library produced through the Knockout All Project (KOAP), providing gene-specific knockout and conditional knockout models across the entire mouse genome
• Disease Mouse Models — spontaneous, induced, and genetically engineered models recapitulating specific human disease pathophysiology across oncology, metabolic, autoimmune, cardiovascular, neurological, and rare disease indications
• Immunodeficient Mouse Models — NOD/SCID, NCG, and related immunocompromised strains suitable for human cell and tumour engraftment, humanised immune system modelling, and PDX studies
• Germ-Free Mouse Models — gnotobiotic and germ-free mice produced and maintained in isolator facilities, supporting microbiome and gut ecology research
• Tool Mice — reporter mice, Cre driver lines, inducible expression models, and other genetic tools used to enable conditional and cell type-specific experiments
• Wild Mouse Project — models generated from wild-type mouse populations supporting studies of genetic diversity and natural variation
• NeoMab® Fully-Human Antibody Transgenic Mouse — proprietary transgenic platform enabling the discovery of fully human monoclonal antibodies directly in vivo

Custom Mouse Model Generation Services

• CRISPR/Cas9-mediated gene editing for point mutations, insertions, deletions, and large fragment knock-ins
• Conditional allele design, including loxP-flanked (floxed) constructs for tissue-specific or inducible knockout
• Humanised mouse model generation, including target gene humanisation and human immune system reconstitution models
• Transgenic model generation and ES cell-based targeting

Preclinical Testing Services

• In vivo pharmacology and drug efficacy evaluation across oncology (syngeneic, CDX, and PDX tumour models), immunology, metabolism, neuroscience, and cardiovascular disease
• Mouse phenotyping services including metabolic, behavioural, cardiovascular, and immunological phenotyping panels
• Patient Derived Xenograft (PDX) model establishment and in vivo efficacy evaluation in PDX systems

Germ-Free and Microbiome Services

• Germ-free and gnotobiotic model production and maintenance
• Microbial colonisation studies, microbiome transfer experiments, and gut microbiota research services

Cell Line and Customisation Services

• Cancer cell line development for CDX model generation
• Cell line engineering and customisation for in vivo implantation studies

Custom Breeding Services

• Colony maintenance, expansion, and timed breeding for client-owned or GemPharmatech-catalogue strains
• Cryopreservation (sperm and embryo) and re-derivation services

Animal Quality Testing Services

• Health monitoring and pathogen surveillance for SPF colonies, supporting health certification for model transfer and shipping

NeoMab® Antibody Discovery Service

• Full-service antibody discovery programme using the NeoMab® transgenic platform, from immunisation through to lead antibody identification and characterisation

GemPharmatech occupies a structurally advantaged position in the global preclinical research services market as the owner and operator of the world’s largest collection of genetically engineered mouse models, a resource built over eight years through systematic genome-wide knockout programmes and disease model generation. The scale of the KOAP library — covering knockout alleles across the full mouse genome — means that researchers requiring a specific gene-modified model are more likely to find it available off-the-shelf from GemPharmatech than from any other single provider, reducing lead times from months to weeks and eliminating the cost and uncertainty of de novo model generation for a large proportion of routine requests. The founding team’s deep connection to China’s National Genetic Engineering Mouse Resource Center has provided both scientific credibility and access to nationally funded model generation infrastructure, establishing a head start in catalogue depth that competitors would require substantial time and capital to replicate. The US operational entity, led by experienced CRO management with backgrounds at Charles River, LabCorp Drug Development, and The Jackson Laboratory, signals a clear intent to convert catalogue assets into sustained commercial relationships with North American pharmaceutical and biotech clients.